Outlier in a BE study [Outliers]

posted by riteshsrmc  – India, 2014-01-16 13:44 (3354 d 09:11 ago) – Posting: # 12177
Views: 8,891

Hi Auditor,

By the way to which agency you are filing the product? Agreed with Dan! EMEA has clearly defined the situation in guidance. I would suggest you to look at FDA perspective as well, if you are filing to FDA. FDA does not encourage redosing to handle outliers subjects incase of non-replicate design study wherein you may carry out redosing incase of replicate design. You should be clear they way agency look at the data with or without outliers.

Complete thread:

UA Flag
 Admin contact
22,550 posts in 4,724 threads, 1,606 registered users;
17 visitors (0 registered, 17 guests [including 7 identified bots]).
Forum time: 22:56 CET (Europe/Vienna)

That which is static and repetitive is boring.
That which is dynamic and random is confusing.
In between lies art.    John Locke

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz